Home | AI powered stock trade ideas | Market Signals | Breaking Out | New Green Signal Stocks | Recent Red Arrow Top Signals | Recent Green Arrow Bottom Signals | Near Term Bottom Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

Recently Featured Stock Charts
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart


All Chart Prices as of Previous Day Close

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Last Price: 17.87 - Change: 0.08 - Change %: 0.4497
04/17/2024 16:13:00 EST

Organon & Co (OGN)

Industry: Drug Manufacturers - General

Price Support Resistance

In the past 20 trading days, OGN has been trading in a range between $18.80 and $17.45 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

The AI powered stock chart is in a Yellow zone which means the stock is transitioning zones. We would avoid this stock currently.

Upside / Downside Potential

Organon & Co $OGN entered a Yellow zone 2 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $29.29, a potential upside of 63.91% from the recent price of 17.87. Our AI powered stock target predictor currently has a target price of $16.47 a potential move of -8%. The stock is trading 29.88% (potential upside) below its 52 week high of $23.21 and 67.48 % (potential downside) above its 52 week low of $10.67 - based on the recent price.

Company Summary

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

OGN Website


Organon (OGN) Advances While Market Declines: Some Information for Investors
In the latest trading session, Organon (OGN) closed at $17.71, marking a +1.49% move from the previous day.
Source: Zacks Investment Research
Mon, 15 Apr 2024 19:21:16 -0400
Sentiment: Neutral
Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks
With the S&P 500 trading close to its 50-day moving average, it's wise for investors to place bets on safe stocks such as Iron Mountain (IRM), Organon (OGN), and International Business Machines (IBM).
Source: Zacks Investment Research
Fri, 12 Apr 2024 09:11:04 -0400
Sentiment: Positive
Why the Market Dipped But Organon (OGN) Gained Today
In the most recent trading session, Organon (OGN) closed at $18.16, indicating a +1.68% shift from the previous trading day.
Source: Zacks Investment Research
Mon, 08 Apr 2024 19:21:15 -0400
Sentiment: Positive
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024.
Source: Business Wire
Mon, 08 Apr 2024 06:15:00 -0400
Sentiment: Neutral
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint.
Source: Business Wire
Mon, 08 Apr 2024 06:00:00 -0400
Sentiment: Neutral
Instituions Institution %: 80.03
Last QTR Institution change: 28115958

Insiders %: 0.144
Insiders Purchases last QTR: 2720
Insiders Sales last QTR: 0
Insiders Net last QTR: 2720

Analyst Ratings
Target Price: 29.29
Overall Rating: 3.3333
Strong Buys (5): 1
Buys (4): 3
Holds (3): 3
Sells (2): 2
Strong Sells (1): 0

52 Week Hi: 23.214
52 Week Low: 10.6714
Beta: 0.79
50 Day MA: 17.8424
200 Day MA: 17.2726

Earnings / Revenue Trends
Qtr Earnings Growth YOY: 4.06
Qtr Revenue Growth YOY: 0.076
Forward PE: 5.0302
Trailing PE: 4.4586

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!


Stock Analyzed Each Night


Easily Upload Track Your Stocks


See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.